Information for healthcare professionals
This drug should be administered by appropriately trained healthcare professionals familiar with its actions, characteristics, and hazards.
In Canada, neuromuscular blockers are commonly supplied with a distinctive red ferrule (metal seal on vial) with white lettering: “Warning: Paralyzing Agent” or “Paralyzing Agent”. Canadian healthcare professionals who administer NMBs are accustomed to this labelling and packaging practice, which has been adopted by industry as a strategy to readily identify NMBs so that they are not confused with other products.
Foreign NMB products may have ferrules that aren’t red. This is the case for US-labelled Pancuronium Bromide Injection, USP (see
Appendix A). This non-standard labelling and packaging may increase the risk of errors in which NMBs are inadvertently selected and administered to patients.
Health Canada is aware of domestic and international reports of NMB mix-ups causing serious harm including death; some of these errors are related to differences in the labelling and packaging of these products.
Proper selection of intended product must be confirmed to avoid confusion with other injectable solutions.
For complete product information, please refer to the
US Pancuronium Bromide Prescribing Information.
Action taken by Health Canada
The Minister of Health signed the
Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in relation to COVID-19. Drugs included on the List of Drugs for Exceptional Importation and Sale referenced in the Interim Order are eligible for the exceptional importation and sale provisions provided for in the Interim Order. Health Canada has added Pancuronium Bromide Injection, USP to this list, which permits the importation and sale of US-labelled Pancuronium Bromide Injection.
Health Canada has worked with Pfizer Canada ULC to prepare this alert for Pancuronium Bromide. Health Canada is communicating this important safety information to healthcare professionals and Canadians via the
Recalls and Safety Alerts Database on the Healthy Canadians Web Site. This communication update will be further distributed through the MedEffect™ e-Notice email notification system, as well as through social media channels, including LinkedIn and Twitter.